Illumina, Inc.  

(Public, NASDAQ:ILMN)   Watch this stock  
Find more results for ilmn
135.45
-0.77 (-0.57%)
Apr 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 133.66 - 138.33
52 week 54.84 - 183.30
Open 136.93
Vol / Avg. 1.12M/2.38M
Mkt cap 17.39B
P/E 157.75
Div/yield     -
EPS 0.86
Shares 128.37M
Beta 0.43
Inst. own 119%
May 28, 2014
Illumina, Inc. Annual Shareholder Meeting - 1:00PM EDT - Add to calendar
Apr 22, 2014
Q1 2014 Illumina, Inc. Earnings Conference Call - 5:30PM EDT - Add to calendar
Apr 22, 2014
Q1 2014 Illumina, Inc. Earnings Release - 4:00PM EDT - Add to calendar
Mar 6, 2014
Illumina Inc at Morgan Stanley Technology, Media & Telecom Conference - Webcast
Mar 5, 2014
Illumina Inc at Cowen Health Care Conference - Webcast
Jan 28, 2014
Q4 2013 Illumina, Inc. Earnings Conference Call - Webcast
Jan 28, 2014
Q4 2013 Illumina, Inc. Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin 20.83% 8.82%
Operating margin 19.05% 9.44%
EBITD margin - 24.77%
Return on average assets 11.09% 4.49%
Return on average equity 22.25% 8.79%
Employees 3,000 -
CDP Score - -

Address

5200 Illumina Way
SAN DIEGO, CA 92122
United States - Map
+1-858-2024500 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Illumina, Inc. (Illumina) is a developer and manufacturer of life science tools and integrated systems for the analysis of genetic variation and function. The Company provides a line of genetic analysis solutions, with products and services that serve a range of interconnected markets, including sequencing, genotyping, gene expression, and molecular diagnostics. The Company is organized in two business segments: Life Sciences and Diagnostics. Its Life Sciences business unit includes all products and services related to the research market, namely the product lines based on its sequencing, BeadArray, VeraCode, and real-time PCR technologies. Its Diagnostics business unit focuses on molecular diagnostics. In February 2014, Illumina, Inc. announced that Novogene purchased one HiSeq X Ten. In March 2014, WuXi Genome Center has purchased Illumina HiSeq X Ten sequencing system.

Officers and directors

William H. Rastetter Ph.D. Chairman of the Board
Age: 65
Bio & Compensation  - Reuters
Francis A. deSouza President, Director
Age: 42
Bio & Compensation  - Reuters
Jay T. Flatley Chief Executive Officer, Director
Age: 61
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Marc A. Stapley Chief Financial Officer, Senior Vice President
Age: 43
Bio & Compensation  - Reuters
David R. Walt Ph.D. Chairman - Scientific Advisory Board, Independent Director
Age: 60
Bio & Compensation  - Reuters
Mostafa Ronaghi Ph.D. Chief Technology Officer, Senior Vice President
Age: 44
Bio & Compensation  - Reuters
Charles Dadswell Senior Vice President, General Counsel, Secretary
Bio & Compensation  - Reuters
Gregory F. Heath Ph.D. Senior Vice President, General Manager - Diagnostics
Age: 55
Bio & Compensation  - Reuters
Christian O. Henry Senior Vice President, General Manager - Genetic Analysis
Age: 45
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Mark L. Lewis Senior Vice President, General Manager - Molecular Biology and PCR
Age: 60
Bio & Compensation  - Reuters